IL15 synergizes with radiotherapy to reprogram the tumor immune contexture through a dendritic cell connection

ABSTRACT

IL15 is a key cytokine for the activation and survival of anti-tumor effectors CD8⁺ T and NK cells. Recently published preclinical studies demonstrate that the therapeutic activity of IL15 requires conventional dendritic cells type 1 (cDC1). Radiotherapy cooperates with IL15 by enhancing cDC1 tumor infiltration via interferon type 1 activation.

KEYWORDS:

• IL-15
• radiotherapy
• dendritic cells
• interferon type 1
• CD8 T-cells

Disclosure of potential conflicts of interest

The authors declared that no conflict of interest exists related to this work, but S.D. has received honorarium from Lytix Biopharma, EMD Serono, and Mersana Therapeutics for advisory service, and research grants from Lytix Biopharma and Nanobiotix. EGM has served as consultant or speaker for Roche, AstraZeneca, Clovis and Pharmamar, research funding from Roche and financial support from AstraZeneca, Roche, Pharmamar, Pfizer, Bristol Meyer Squibb and MSD.

Additional information

Funding

This work was supported by grants from the NIH (R01 CA198533 and R01CA201246), The Chemotherapy Foundation and the Breast Cancer Research Foundation (to S.D.). Breast Cancer Research Foundation (to S.D.). Elena García-Martínez was supported by a grant from the Spanish Breast Cancer Group (GEICAM)